International Clinical Trial: Efficacy and safety of standard therapy combined with all-site radiotherapy for GG5 metastatic prostate cancer

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119199) titled 'Efficacy and safety of standard therapy combined with all-site radiotherapy for GG5 metastatic prostate cancer' on Feb. 24.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Peking University First Hospital

Condition: Prostate Cancer

Intervention: Standard treatment group:None

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-01

Target Sample Size: Standard treatment group:30;Intensive Treatment Group:146;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=292481

Published by HT Digital Content...